Drug-Free Macromolecular Therapeutics

Update item information
Identifier drug-free_macromolecular_therapeutics
Title Drug-Free Macromolecular Therapeutics
Creator Kopeček, J.; Pharmaceutics and Pharmaceutical Chemistry; College of Pharmacy; University of Utah Health
Subject Diffusion of Innovation; Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Apoptosis; Molecular Targeted Therapy; Antibodies; Cluster Analysis; Intrinsic Factor; Chemistry, Pharmaceutical; Knowledge Discovery
Keyword Drug Discovery
Image Caption Drug-free macromolecular therapeutics.
Description Monoclonal antibody therapy has numerous benefits but can lack efficacy, often because monovalent binding of antibodies to specific receptors fails to translate into an active response. The Kopeček laboratory has built on their track record in polymeric drug delivery to develop a novel approach to therapeutic design, termed "Drug-Free Macromolecular Therapeutics (DFMT)". DFMT exploits the selective Watson-Crick base-pairing properties of oligonucleotides to tether receptor-prebound antibodies to receptors at the cell surface. This two-step self-assembly strategy uses both sequential receptor binding and clustering to broaden and strengthen antibody functions, including the anti-CD20 antibody obinutuzumab, which increases apoptotic cell death in cancer cells both in vitro and in vivo. Their second-generation DFMT combines the activation pathways of Type I and Type II antibodies into one system and will be developed into a new class of drug-free macromolecular therapeutics suitable for a broad spectrum of B-cell malignancies, including treatment-resistant tumors.
Relation is Part of 50 Basic Science Discoveries in 5 Years- 2019
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2020
Date 2019
Type Image
Format image/jpeg
Rights Management Copyright © 2020, University of Utah, All Rights Reserved
Language eng
ARK ark:/87278/s6dz5zdr
References 1.) Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Zhang R, Yang J, Sima M, Zhou Y, Kopeček J. Proc Natl Acad Sci USA. 2014 Aug;111(33):12181. https://pubmed.ncbi.nlm.nih.gov/25092316/ 2.) Backbone degradable N-(2-Hydroxypropyl)methacrylamide copolymer conjugates with gemcitabine and paclitaxel: impact of molecular weight on activity toward human ovarian carcinoma xenografts. Yang J, Zhang R, Pan H, Li Y, Fang Y, Zhang L, Kopeček J. Mol Pharm. 2017 May;14(5):1384. https://pubmed.ncbi.nlm.nih.gov/28094954/ 3.) Broadening and enhancing functions of antibodies by self-assembling multimerization at cell surface. Li L, Wang J, Li Y, Radford DC, Yang J, Kopeček J ACS Nano. 2019 Oct;13(10):11422. https://pubmed.ncbi.nlm.nih.gov/31553883/
Setname ehsl_50disc
Date Created 2020-08-13
Date Modified 2020-11-17
ID 1589398
Reference URL https://collections.lib.utah.edu/ark:/87278/s6dz5zdr